518048-02-7

Basic information

• Product Name: BENZYL [1-[4-[[(4-FLUOROBENZYL)AMINO]CARBONYL]-5-HYDROXY-1-METHYL-6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL]-1-METHYLETHYL]CARBAMATE
• Synonyms: BENZYL [1-[4-[[(4-FLUOROBENZYL)AMINO]CARBONYL]-5-HYDROXY-1-METHYL-6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL]-1-METHYLETHYL]CARBAMATE;Benzyl 2-(4-(4-fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-ylcarbamate;[1-[4-[[(4-Fluorobenzyl)aMino]carbonyl]-5-hydroxy-1-Methyl-6-oxo-1,6-dihydropyriMidin-2-yl]-1-Methylethyl]benzyl carbaMate;benzyl N-[2-(4-{[(4-fluorophenyl)Methyl]carbaMoyl}-5-hydroxy-1-Methyl-6-oxo-1,6-dihydropyriMidin-2-yl)propan-2-yl]carbaMate;N-[1-[4-[[[(4-Fluorophenyl)Methyl]aMino]carbonyl]-1,6-dihydro-5-hydroxy-1-Methyl-6-oxo-2-pyriMidinyl]-1-Methylethyl]-carbaMic Acid PhenylMethyl Ester;Benzyl [1-[4-[[(4-fluorobenzyl)amino]carbonyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl;6.Benzyl[1-[4-[[(4-Fluorobenzyl)amino]carbonyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl]-1-methylethyl]carbamate;amino]carbonyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl]-1-methylethyl]carbamate
• CAS NO: 518048-02-7
• Molecular Formula: C24H25FN4O5
• Molecular Weight: 468.48
• EINECS: 1592732-453-0
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;intermediate
• Mol File: 518048-02-7.mol
• Article Data: 13

Chemical Properties

• Melting Point: 167-170°C
• Appearance: off-white solid
• Density: 1.304 g/cm³
• Refractive Index: 1.602
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 4.50±1.00(Predicted)
• CAS DataBase Reference: BENZYL [1-[4-[[(4-FLUOROBENZYL)AMINO]CARBONYL]-5-HYDROXY-1-METHYL-6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL]-1-METHYLETHYL]CARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: BENZYL [1-[4-[[(4-FLUOROBENZYL)AMINO]CARBONYL]-5-HYDROXY-1-METHYL-6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL]-1-METHYLETHYL]CARBAMATE(518048-02-7)
• EPA Substance Registry System: BENZYL [1-[4-[[(4-FLUOROBENZYL)AMINO]CARBONYL]-5-HYDROXY-1-METHYL-6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL]-1-METHYLETHYL]CARBAMATE(518048-02-7)

Safety Data

• Hazardous Substances Data: 518048-02-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
BENZYL [1-[4-[[(4-FLUOROBENZYL)AMINO]CARBONYL]-5-HYDROXY-1-METHYL-6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL]-1-METHYLETHYL]CARBAMATE is used as an intermediate in the synthesis of HIV-integrase inhibitors for the development of antiretroviral drugs. These inhibitors play a vital role in suppressing the replication of the HIV virus, thereby helping to manage and treat HIV/AIDS.
Used in Research and Development:
In the field of research and development, BENZYL [1-[4-[[(4-FLUOROBENZYL)AMINO]CARBONYL]-5-HYDROXY-1-METHYL-6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL]-1-METHYLETHYL]CARBAMATE serves as a valuable compound for exploring new avenues in the fight against HIV. Its unique chemical structure allows researchers to investigate its potential in creating novel therapeutic strategies and understanding the underlying mechanisms of HIV-integrase inhibition.
Used in Chemical Synthesis:
BENZYL [1-[4-[[(4-FLUOROBENZYL)AMINO]CARBONYL]-5-HYDROXY-1-METHYL-6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL]-1-METHYLETHYL]CARBAMATE is also utilized in various chemical synthesis processes, where its specific functional groups and structural features can be exploited to create a range of derivative compounds with potential applications in different industries, including pharmaceuticals, materials science, and agrochemicals.

InChI:InChI=1/C24H25FN4O5/c1-24(2,28-23(33)34-14-16-7-5-4-6-8-16)22-27-18(19(30)21(32)29(22)3)20(31)26-13-15-9-11-17(25)12-10-15/h4-12,30H,13-14H2,1-3H3,(H,26,31)(H,28,33)

Upstream product

• 1719-57-9 Chloro(chloromethyl)dimethylsilane 
• 140-75-0 para-fluorobenzylamine 
• 519028-33-2 benzyl 2-(4-(4-fluorobenzylcarbamoyl)-5-hydroxy-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-ylcarbamate 
• 77-78-1 dimethyl sulfate 
• 100134-82-5 (cyano-dimethyl-methyl)carbamic acid benzyl ester 
• 1064707-10-3 C₁₈H₂₃N₃O₇ 
• 1028026-73-4 C₁₈H₂₃N₃O₇ 
• 1028026-63-2 C₁₈H₂₃N₃O₇ 
• 518047-98-8 [1-(N'-hydroxycarbamimidoyl)-1-methyl-ethyl]carbamic acid benzyl ester 
• 519028-33-2 {1-[4-(4-fluoro-benzylcarbamoyl)-5,6-dihydroxy-pyrimidin-2-yl]-1-methyl-ethyl}-carbamic acid benzyl ester 
• 74-88-4 methyl iodide 
• 518048-01-6 methyl 5-(benzoyloxy)-2-(1-{[(benzyloxy)carbonyl]amino}-1-methylethyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate 
• 1774-47-6 trimethylsulfoxonium iodide 
• 888504-27-6 2-(1-benzyloxycarbonylamino-1-methyl-ethyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid methyl ester 

Downstream Products

• 1193687-88-5 ethyl (2-(4-(4-fluorobenzylcarbamoyl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl)propan-2-ylcarbamoyl)formate 

Relevant articles and documents

(Chloromethyl)dimethylchlorosilane-KF: A Two-Step Solution to the Selectivity Problem in the Methylation of a Pyrimidone Intermediate en Route to Raltegravir

The present work describes a two-step process, namely, silylation with (chloromethyl)dimethylchlorosilane and desilylation, to address the selectivity problem in the N-methylation of a pyrimidone intermediate toward the synthesis of the raltegravir active pharmaceutical ingredient. The said methodology delivers the desired drug substance in which the O-methylated impurity content is below the detection limit by high-performance liquid chromatography analysis. Moreover, this two-step, one-pot procedure provides an apparent advantage in terms of environmental impact with respect to the optimum approach described in the literature, while it compares equally well in terms of cost and operational simplicity.

A newfangled synthesis of integrase inhibitor drug substance raltegravir potassium

Raltegravir sodium synthesis was achieved from its one of the key starting materials with retro synthetic approach, in which without using its critical starting material chemically known as 5-methyl-1,3,4-oxadiazole-2-carbonyl chloride and which is more unstable during the synthesis of raltegravir potassium. Almost all the existed literatures commonly using this starting material in its synthesis even it is having a stability issue and hence to achieve a stable and economically viable synthesis. The current research describes a new route of synthesis by constructing an oxadiazole ring in a retro synthetic manner.

PROCESS FOR PREPARING COMPOUNDS USEFUL AS INTERMEDIATES FOR THE PREPARATION OF RALTEGRAVIR

The invention discloses a novel and selective methylation process used in the preparation of Raltegravir and intermediates. Further disclosed is an improved method for the reaction of intermediate amine compound of formula IIb with oxadiazole intermediate compound of formula V.

PROCESSES FOR PREPARING RALTEGRAVIR AND INTERMEDIATES IN THE PROCESSES

The present invention provides a process for preparing benzyl-2-(4-(4- fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2- ylcarbamate (RLT-8), a process for preparing Raltegravir via RLT-8, a process for preparing methyl 2-(2-(benzyloxycarbonylamino)propan-2-yl)-5 -hydroxy-1-methyl-6- oxo-1,6-dihydropyrimidine-4-carboxylate (RLT-7'), a process for preparing Raltegravir via RLT-7', and a process for preparing crystalline form V of Raltegravir potassium.

Identification, synthesis, and strategy for minimization of potential impurities observed in raltegravir potassium drug substance

Multiple sources of anticipated degradation and process impurities of raltegravir potassium drug substance observed during the laboratory optimization and later during its bulk synthesis are described in this article. The impurities were monitored by UPLC, and their structures are tentatively assigned on the basis of fragmentation patterns in LC-MS and NMR spectroscopy. Most of the impurities are synthesized, and their assigned constitutions were confirmed by co-injection in UPLC. In addition to the formation, synthesis, and characterization, strategy for minimizing these impurities to the level accepted by ICH is also described. We feel that our study will be helpful to the generic industry for obtaining chemically pure raltegravir potassium.

Development of a second-generation, highly efficient manufacturing route for the HIV integrase inhibitor raltegravir potassium

A manufacturing route for the synthesis of raltegravir potassium 1 was developed via a thermal rearrangement of amidoxime DMAD adducts 6 to construct the key, highly functionalized hydroxypyrimidinone core 7. Utilizing this route 1 was prepared in nine linear chemical steps with 22% overall yield. A second-generation synthesis was subsequently developed that solved the key chemical, productivity, and environmental impact issues of the initial synthesis. Highlights of the new synthesis include a highly selective methylation, 3-4-fold higher productivity, and a 65% reduction of combined organic and aqueous waste produced. The efficient second-generation manufacturing route provides raltegravir potassium 1 in 35% overall yield.

PROCESS FOR PREPARING N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDES

Processes for preparing certain N-arylalkyl-1-(alkyl or aralkyl)-2-acylaminoalkyl- 5-hydroxy -6-oxo-1,6-dihydropyrimidine-4-carboxamides are disclosed. In one embodiment, the process comprises acylating the free amine in the corresponding N-arylalkyl-1-(alkyl or aralkyl)- 2-aminoalkyl-5-ester protected hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxamide and then deprotecting the 5-hydroxy by base hydrolysis. The hydroxypyrimidinone carboxamide products of the process are HTV integrase inhibitors which are useful for treating HTV infection, treating AIDS, or delaying the onset or progression of AIDS. Certain esterified N-arylalkyl hydroxypyrimidinone carboxamides that can be employed as process intermediates are also disclosed.

Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection

Human immunodeficiency virus type-1 (HIV-1) integrase is one of the three virally encoded enzymes required for replication and therefore a rational target for chemotherapeutic intervention in the treatment of HIV-1 infection. We report here the discovery of Raltegravir, the first HIV-integrase inhibitor approved by FDA for the treatment of HIV infection. It derives from the evolution of 5,6-dihydroxypyrimidine-4-carboxamides and N-methyl-4- hydroxypyrimidinone-carboxamides, which exhibited potent inhibition of the HIV-integrase catalyzed strand transfer process. Structural modifications on these molecules were made in order to maximize potency as HIV-integrase inhibitors against the wild type virus, a selection of mutants, and optimize the selectivity, pharmacokinetic, and metabolic profiles in preclinical species. The good profile of Raltegravir has enabled its progression toward the end of phase III clinical trials for the treatment of HIV-1 infection and culminated with the FDA approval as the first HIV-integrase inhibitor for the treatment of HIV-1 infection.

TASTE-MASKED TABLETS AND GRANULES

Orally administered, taste-masked tablets and granules contain (a) a hydroxypyrimidinone carboxamide, a hydroxy-tetrahydropyridopyrimidinone carboxamide, or a related carboxamide compound, or a pharmaceutically acceptable salt thereof, (b) a taste-masking polymer, (c) a superdisintegrant, and optionally other excipients. The carboxamide compound is an HIV integrase inhibitor, and the tablets and granules are suitable for use in the inhibition of HIV integrase, the treatment or prophylaxis of HIV infection, and the treatment or prophylaxis or delay in the onset of AIDS.

Potassium salt of an HIV integrase inhibitor

Potassium salts of Compound A and methods for their preparation are disclosed, wherein Compound A is of formula: Compound A is an HIV integrase inhibitor useful for treating or prophylaxis of HIV infection, for delaying the onset of AIDS, and for treating or prophylaxis of AIDS.